The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis

Sponsor
Incyte Corporation
Study ID
NCT04839380
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ruxolitinib cream — DRUG
    ruxolitinib cream 1.5% will be applied twice daily as a thin film

Study Details

The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.

Key Dates

Start date
Oct 12, 2021
Status verified
Oct 2023
Primary completion
Nov 18, 2022
Completion
Nov 18, 2022

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group : Ruxolitinib
    ruxolitinib cream 1.5% will be applied twice daily as a thin film.

Primary Outcome Measure

Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application) [ Time Frame: Baseline; Day 2 ]

Related Studies